Skip to main content

Mirviss Jeffrey B.'s Form 4 filing

Boston Scientific Corp (BSX) · filed Aug 30, 2023

Accession no.
0001225208-23-008555
Filed
Aug 30, 2023
Trade date
Aug 28-29, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $996.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mirviss Jeffrey B.CIK 0001566094Officer (EVP&Pres, Periph Intervent)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 28, 2023Common StockSSaleDisposed−13,971$53.14−$742,418.9465,245Direct
Aug 29, 2023Common StockSSaleDisposed−4,657$54.50F3−$253,806.560,588Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $54.50 to $54.51, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)